• IDELALISIB CHEMBL2216870 FDA ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    Idelalisib
    GS-1101
    CAL-101
    GS-11CAL-101
    40L
    5-FLUORO-3-PHENYL-2-[(1S)-1-(7H-PURIN-6-YLAMINO)PROPYL]QUINAZOLIN-4(3H)-ONE
    5-FLUORO-3-PHENYL-2-[(1S)-1-(3H-PURIN-6-YLAMINO)PROPYL]QUINAZOLIN-4(3H)-ONE
    4(3H)-QUINAZOLINONE, 5-FLUORO-3-PHENYL-2-[(1S)-1-(1H-PURIN-6-YLAMINO)PROPYL]-
    (S)-5-FLUORO-3-PHENYL-2-[1-(9H-PURIN-6-YLAMINO)-PROPYL]-3H-QUINAZOLIN-4-ONE
    (S)-2-(1-(1H-PURIN-6-YLAMINO)PROPYL)-5-FLUORO-3-PHENYLQUINAZOLIN-4(3H)-ONE
    5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]QUINAZOLIN-4-ONE
    CAL101;S2226;870281-82-6
    BRD-K60866521-001-01-4
    Q-4533
    D10560
    X7435
    FT-0699107
    ST2408278
    SMR004702787
    KB-48629
    HY-13026
    HE106857
    BC638838
    AK145603
    AJ-64558
    NCGC00262603-01
    CAL-101-SUPPLIED BY SELLECK CHEMICALS
    RL05396
    PB25727
    LS41100
    GS 1101
    CS-0256
    BCP9000471
    AKOS022186334
    ZINC13986658
    GS1101
    BDBM50403068
    ABP000109
    AOB87313
    BCPP000307
    MOLPORT-016-633-355
    IFSDAJWBUCMOAH-HNNXBMFYSA-N
    CAL-101/CAL101
    YG57I8T5M0
    QCR-36
    GTPL6741
    C22H18FN7O
    SCHEMBL356400
    IDELALISIB (JAN/USAN/INN)
    MLS006010985
    CC-41
    IDELALISIB [USAN:INN]
    TUBE701
    S2226_SELLECK
    ZYDELIG (TN)
    5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE
    5-FLUORO-3-PHENYL-2-((1S)-1-(9H-PURIN-6-YLAMINO)PROPYL)-4(3H)-QUINAZOLINONE
    ZYDELIGREG
    5-FLUORO-3-PHENYL-2-((S)-1-(9H-PURIN-6-YLAMINO)-PROPYL)-3H-QUINAZOLIN-4-ONE
    5-FLUORO-3-PHENYL-2-[(1S)-1-(7H-PURIN-6-YLAMINO)PROPYL]QUINAZOLIN-4-ONE
    CAL-101, CAL101
    1146702-54-6
    CAL-101 (IDELALISIB, GS-1101)
    (S)-2-(1-(9H-PURIN-6-YLAMINO)PROPYL)-5-FLUORO-3-PHENYLQUINAZOLIN-4(3H)-ONE
    CHEBI:82701
    UNII-YG57I8T5M0
    (S)-2-(1-((9H-PURIN-6-YL)AMINO)PROPYL)-5-FLUORO-3-PHENYLQUINAZOLIN-4(3H)-ONE
    CAL101
    ZYDELIG
    CAL 101
    870281-82-6
    11625818
    DCL001091
    DB09054
    178103352
    6741

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    Drug Categories therapeutic uses
    Drug Categories quinazolines
    Drug Categories pharmacologic actions
    Drug Categories p-glycoprotein/abcb1 substrates
    Drug Categories p-glycoprotein/abcb1 inhibitors
    Drug Categories molecular mechanisms of pharmacological action
    Drug Categories immunosuppressive agents
    Drug Categories heterocyclic compounds, 2-ring
    Drug Categories heterocyclic compounds
    Drug Categories enzyme inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors (strong)
    Drug Categories cytochrome p-450 cyp3a inhibitors
    Drug Categories cytochrome p-450 cyp3a inducers
    Drug Categories cytochrome p-450 cyp2c8 inhibitors
    Drug Categories cytochrome p-450 cyp2c19 inhibitors
    Drug Categories cytochrome p-450 cyp2b6 inducers
    Drug Categories combined inhibitors of cyp3a4 and p-glycoprotein
    Drug Categories class ia phosphatidylinositol 3-kinase, antagonists & inhibitors
    Drug Categories chemical actions and uses
    Drug Categories bcrp/abcg2 substrates
    Drug Categories antineoplastic and immunomodulating agents
    Drug Categories antineoplastic agents
    Drug Groups approved
    Drug Type small molecule
    Drug Class Kinase Inhibitors
    (5 More Sources)